MALVERN, Pa.--(BUSINESS WIRE)--Venatorx Pharmaceuticals today announced that it was named one of the “2020 Best Places to Work” in the medium-sized company category in the Greater Philadelphia area by the Philadelphia Business Journal.
The Philadelphia Business Journal, in partnership with Quantum Workplace, honors companies based on a scoring benchmark, which reflects employee response rates as well as employee rankings of work environment, people, personal growth, and professional development. Quantum Workplace employee surveys measure each company’s culture, from compensation and benefits to trust in senior leadership.
“This year marks Venatorx’s 10th Anniversary. Being named a ‘Best Places to Work’ for the third year in a row comes at a fitting time to acknowledge our team’s unwavering commitment to bring lifesaving antibiotics and antiviral medicines to patients around the globe,” said Christopher J. Burns, Ph.D., President and CEO of Venatorx. “The COVID-19 pandemic has tested our will and presented strenuous and challenging environments through which our team continues to demonstrate mutual respect, steadfast determination and exceptional resilience. We are honored by this recognition and grateful to our employees for being ambassadors of our mission.”
Headquartered in the suburbs of Philadelphia, Venatorx has grown from three founders in 2010 to over 70 employees in 2020 and is actively seeking driven, passionate and entrepreneurial-minded professionals for open positions in CMC, Regulatory Affairs, Operations, Discovery, and Development to support its aggressive strategic growth plan.
About Venatorx Pharmaceuticals, Inc.
Venatorx is a private pharmaceutical company focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant bacterial infections and hard-to-treat viral infections. Founded in 2010, Venatorx has built a world-class in-house R&D organization that has filed over 100 patents spanning multiple research programs. Venatorx’s clinical and preclinical antibacterial and antiviral programs have been supported by funding from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH); Wellcome Trust; the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Service (HHS); the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA); CARB-X; the Global Antibiotic Research and Development Partnership (GARDP); as well as private equity investment from Versant Ventures, Abingworth and Foresite Capital. For more information, please visit www.venatorx.com.
